Lygidakis N J, Singh Gurusharan, Bardaxoglou E, Dedemadi G, Sgourakis G, Nestoriois J, Malliotakis A, Pedonomou M, Safioleas M, Solomou E K, Grigorakos L, Vrachnos P
Department of Surgical Oncology, Henry Dunant Hospital, Athens, Greece.
Hepatogastroenterology. 2004 May-Jun;51(57):689-96.
BACKGROUND/AIMS: To evaluate the long-term outcome of a multidisciplinary approach for advanced Klatskin tumor involving the hepatic hilus.
A retrospective analysis was undertaken in 110 patients between 1993 and 2003. The patients were divided into Group A (n=42) and Group B (n=58). Group A patients underwent local excision of the tumor and Group B patients underwent combined tumor and liver resection with or without resection of the regional vascular structures. On admission, all patients underwent percutaneous transhepatic biliary drainage. Where hepatectomy was planned, portal vein branch ligation and transection was done ipsilateral to the liver lobe where the tumor was present. An arterial catheter was introduced into the hepatic artery at the end of the surgery, for adjuvant locoregional immunochemotherapy, which was carried out in all patients. The second-stage resectional surgery was carried out 35 days later.
The overall mean survival for Group A patients was 29 months (range 14 to 76). The mean disease-free survival was 28 months (range 10-52). Five-year survival rate was 5% and five-year disease-free survival was 0%. The overall mean survival for Group B patients was 39 months (range 28 to 79). The mean disease-free survival was 32 months (range 17-72). Five-year survival rate was 20% and five-year disease-free survival was 10%.
The concept of a multidisciplinary approach has significantly improved survival in patients with a grave disease like Klatskin tumor.
背景/目的:评估多学科方法治疗累及肝门部的晚期Klatskin肿瘤的长期疗效。
对1993年至2003年间的110例患者进行回顾性分析。患者分为A组(n = 42)和B组(n = 58)。A组患者接受肿瘤局部切除,B组患者接受肿瘤与肝脏联合切除,可选择或不切除区域血管结构。入院时,所有患者均接受经皮经肝胆道引流。若计划进行肝切除术,则在肿瘤所在肝叶的同侧进行门静脉分支结扎和横断。手术结束时,将动脉导管插入肝动脉,对所有患者进行辅助局部免疫化疗。35天后进行二期切除手术。
A组患者的总体平均生存期为29个月(范围14至76个月)。平均无病生存期为28个月(范围10至52个月)。五年生存率为5%,五年无病生存率为0%。B组患者的总体平均生存期为39个月(范围28至79个月)。平均无病生存期为32个月(范围17至72个月)。五年生存率为20%,五年无病生存率为10%。
多学科方法的理念显著提高了患有Klatskin肿瘤等严重疾病患者的生存率。